Direct to Consumer With a Shopify footprint and readiness for direct sales, Kiwi Bio can monetize FODZYME directly to IBS consumers and explore white label collaborations with other brands, expanding reach through ecommerce and potential subscription models.

Strategic Partnerships Opportunities to license or co-manufacture FODZYME with large digestive health brands and food manufacturers to embed into products such as sauces, snacks, and ready meals, accelerating distribution beyond niche biotech channels.

Clinical Validation Leverage Harvard iLabs recognition and open track finalist status to initiate pilots with gastroenterology clinics and research centers, building clinical credibility that can support insurance coverage discussions and clinician referrals.

Credibility & Funding A small, agile team with revenue in the low to mid millions and early funding presents a compelling case for strategic distributors and investors, enabling faster scaling of sales channels and field partnerships in the consumer health and biotech sectors.

Product Expansion Expand the product footprint to additional FODMAP triggers beyond garlic, onion, wheat, and banana to broaden the addressable market and create cross selling opportunities with broader gut health portfolios.